This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab

Volume: 31, Issue: 3, Pages: 678 - 683
Published: Jul 23, 2020
Abstract
Biologics have been used to treat refractory Takayasu arteritis (TAK), but their efficacy and safety have not been sufficiently evaluated.We extracted clinical information from medical records for TAK patients who were treated with biologics including ustekinumab (UST) at Kyoto University Hospital. We also analysed the patient's genetic backgrounds.Of 163 cases, 12 (7.4%) were treated with infliximab, tocilizumab, or UST (n = 3). Erythrocyte...
Paper Details
Title
Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab
Published Date
Jul 23, 2020
Volume
31
Issue
3
Pages
678 - 683
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.